Cargando…
Access to high cost medicines in Australia: ethical perspectives
Access to "high cost medicines" through Australia's Pharmaceutical Benefits Scheme (PBS) is tightly regulated. It is inherently difficult to apply any criteria-based system of control in a way that provides a fair balance between efficient use of limited resources for community needs...
Autores principales: | Lu, Christine Y, Macneill, Paul, Williams, Ken, Day, Ric |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2412887/ https://www.ncbi.nlm.nih.gov/pubmed/18489760 http://dx.doi.org/10.1186/1743-8462-5-4 |
Ejemplares similares
-
The views of stakeholders on controlled access schemes for high-cost antirheumatic biological medicines in Australia
por: Lu, Christine Y, et al.
Publicado: (2007) -
Recent developments in targeting access to high cost medicines in Australia
por: Lu, Christine Y, et al.
Publicado: (2005) -
The funding and use of high-cost medicines in Australia: the example of anti-rheumatic biological medicines
por: Lu, Christine Y, et al.
Publicado: (2007) -
The ethics of open access publishing
por: Parker, Michael
Publicado: (2013) -
Access to new cancer medicines in Australia: dispelling the myths and informing a public debate
por: Vitry, Agnes, et al.
Publicado: (2016)